Human exposure to Bisphenol A (BPA) is omnipresent. Both the extent of the exposure and its toxicological relevance are controversially discussed. We aim to reliably determine and evaluate the extent of BPA body burden in the German population from 1995 to 2009 based on 600 24 h urine samples and corresponding plasma samples from the Environmental Specimen Bank. We determined total and unconjugated BPA in urine and plasma using on-line solid-phase extraction high-performance liquid chromatography coupled to isotope dilution tandem mass spectrometry with a limit of quantification (LOQ) of 0.1 mg/l. In the stored urines, total BPA was quantifiable in 496% (median: 1.49 mg/l; 95th percentile: 7.37 mg/l), whereas unconjugated BPA was quantifiable only in o15% of the samples. Total BPA concentrations decreased over time, but 24 h urine volumes increased. Therefore, daily intakes calculated from the 24 h urines remained rather constant at a median of 0.037 and a 95th percentile of 0.171 mg BPA/kg body weight/day. In 60 corresponding plasma samples, total BPA levels were generally below the LOQ of 0.1 mg/l and, if quantifiable, most BPA was unconjugated, thus hinting to external contamination. We see total BPA in urine as the most appropriate and robust marker for BPA exposure assessment (if controlled for BPA contamination). Unconjugated BPA in urine and unconjugated or total BPA in plasma where contamination or breakdown of the glucuronide cannot be ruled out are of no value for human exposure assessment.
INTRODUCTION
Bisphenol A (BPA) is a high production volume chemical and is used primarily in manufacturing polycarbonate plastics and epoxy resins and also in the production of polyvinyl chloride (PVC). BPA-derived or BPA-containing products comprise baby bottles, impact-resistant safety equipment, metal food containers with inner coatings, thermal paper or dentistry materials. 1, 2 Various recent human biomonitoring (HBM) studies, among them the US National Health and Nutrition Survey (NHANES), the German Environmental Survey (GerES) and the Canadian Health Measures Survey, determined BPA in urine samples 3--5 and confirmed the omnipresent body burden to BPA in many different population groups worldwide (reviewed in Vandenberg et al. 6 ). Exposure sources to BPA are widespread but contaminated food is believed to be a major contributor. 7--9 HBM is an ideal tool to determine exposure even when the contributions of the different external exposures are unknown, ambiguous or difficult to evaluate, because it represents an integral internal measure of all external exposure sources. 10, 11 BPA is not metabolized in significant amounts by phase I biotransformations in humans, 12 but is rapidly and almost completely conjugated in phase II biotransformations with glucuronides and sulfates. BPA is almost completely excreted in urine as a conjugate, with a terminal half-life of o6 h. 1,13--15 Thus, the ideal biomarker to analyze and quantify exposure to BPA would be BPA-glucuronide. An important advantage of measuring the concentrations of the conjugated metabolite is that it is undoubtedly generated in the human body. Determining conjugated BPA would exclude potential external contaminations by unconjugated BPA from BPA-containing materials during sampling and the analytical process. However, trace-level analysis of conjugated species is rather difficult because of their chemical and physical properties. 7 In human biomonitoring studies aimed to assess exposures, the general approach is to measure the total concentration of the compound (unconjugated plus conjugated species) after hydrolysis of the conjugate(s). Special attention has to be paid to avoid external contamination with the parent compound. 13,16--20 Analyses of unconjugated BPA have been advocated in several studies as a measure of exposure to the toxicologically active compound. However, given the contamination issue with low-level BPA analyses, we regard the analyses of unconjugated BPA as useful and appropriate only in studies strictly controlled for contamination already from the time of sample collection, or toxicological studies performed with labeled BPA. For general population studies with the aim to measure the extent of overall BPA exposure, we regard the determination of total BPA (with a determination of the ratio of unconjugated to total BPA) as more appropriate.
Because the Environmental Specimen Bank (ESB) did not have a special protocol to control for BPA contamination at the time of collection (sampling started in the early 1980s), and because these samples were stored for years (up to decades) with unknown affects on the stability of the conjugates, we decided to measure both the unconjugated and the total BPA concentration (after enzymatic hydrolyses) in a pilot study before the main study. High concentrations of unconjugated BPA relative to conjugated BPA would either indicate to contamination issues during sample collection and storage or to a degradation of conjugated BPA to unconjugated BPA over the storage period. 20 In the pilot study, we therefore tested the conjugation status of BPA in the ESB samples. Given the integrity of the samples, the ESB enables us to retrospectively assess the exposure to BPA and to observe time trends of exposure, as we have done previously with the phthalates 21 or other environmental toxicants. 22 A second asset of ESB is that the urine samples are collected as 24 h urine samples. Unlike most other population-based studies where spot urine samples are collected, variability of either ''diluted'' or ''concentrated'' metabolite levels in urine is not an issue. Based on the 24 h urine samples from ESB, the daily exposure to BPA and therefore also the daily intake to BPA can be deduced both easily and reliably. 12 By comparing the calculated daily BPA intake with environmental health benchmarks like the reference dose (RfD) of the EPA, the tolerable daily intake (TDI) of the European Union or other doses determined in scientific studies found to have health effects, one can estimate and thus objectify the risk associated with the actual exposure to BPA. In a small follow-up study, we also determined BPA (unconjugated and total) in a subset of ESB plasma samples and investigated correlations of BPA in plasma and urine samples.
METHODS

Subjects and Human Specimens
The human specimens (in our case urine and plasma) were collected by the German ESB. The ESB is set up as a permanent national institution under the responsibility of the German Federal Ministry for the Environment, Nature Conservation and Nuclear Safety (BMU) and coordinated by the German Federal Environment Agency (UBA). The main focus of the human part of the German ESB is to document and assess trends of human exposure via the monitoring of body burden and longterm storage of samples under stable deep-freezing conditions. The study protocol of sampling human specimens has been reviewed and approved by the ethics committee of the Medical Association Westfalen-Lippe and the Medical Faculty of the Westphalian Wilhelms-University Muenster. The positive vote was made available to the university partners in the sampling areas Greifswald, Halle/Saale and Ulm for submission to the local ethics committees. All study participants gave written informed consent on standardized forms approved by the same ethics committees. The concept and sampling criteria of the ESB are described in detail elsewhere. 22 In short, samples were mostly taken from students (B120 volunteers per sampling location) from the four participating sampling areas of Mü nster, Greifswald, Halle/Saale and Ulm. Personal data (e.g., sex, age, body height and body weight) as well as information about personal behavior and lifestyle factors (e.g., nutrition and use of chemicals) were collected using a standardized self-reported questionnaire.
All urine specimens were collected as 24 h urine samples in 3 liter vessels. The total 24 h volume was determined by weighing, and standard parameters like density, conductivity and creatinine content were determined routinely. The 24 h urine was aliquoted into polypropylene tubes and pre-frozen at À20 1C. The volunteers also donated B150 ml of blood. From 90 ml of the blood, B30 ml of plasma was separated by centrifugation and aliquoted into polypropylene tubes. All specimens were transported to the permanent storage location of human specimens in Muenster the the following day. There, the polypropylene tubes were stored in a cooling chamber at below À80 1C. Since 2005, all human specimens were archived above liquid nitrogen at temperatures below À150 1C.
In the pilot study, we analyzed 60 urine samples for unconjugated and total BPA with the intention to test the ESB specimens for possible external BPA contamination or degradation of conjugated BPA to unconjugated BPA. These samples were randomly selected from the years 1988 and 2008 (30 samples each) and not stratified according to age and gender. In the main study we analyzed 600 24 h urine samples from the years 1995, 1997, 1999, 2001, 2003, 2005, 2006, 2007, 2008 and 2009 . All samples were predominantly from students (age range 20--30 years) located at the University of Muenster (Germany). Each year, the study population consisted of 30 male and 30 female volunteers. A short population description is given in Table 1 . All urine samples were blinded by the ESB before shipment to the analyzing laboratories at the IPA, Bochum, Germany.
In a follow-up study we analyzed 60 ESB plasma samples for unconjugated and total BPA. Aliquots of the plasma samples were stored the same way as the urine samples above. These plasma samples matched the urine samples analyzed before but were selected by the ESB to reflect the bandwidth of urinary BPA concentrations as well as sampling years of the samples. Again, these samples were blinded by the ESB before shipment and analyses.
Determination of Total BPA in Urine
The total BPA concentration was determined using a high-performance liquid chromatography--mass spectrometry method (on-line SPE HPLC--MS/MS) described previously, 15, 23 with slight modifications. In short, the HPLC system was built up of Agilent 1200 Series modules (Agilent Technologies, Waldbronn, Germany) consisting of a quaternary pump (for the on-line SPE step) and a binary pump (for the chromatographic separation on the analytical column), an auto sampler with a 100 ml Table 1 . Description of the ESB study population (main study).
injection loop and a thermostatted column compartment with a six-port switching valve. The HPLC system was coupled to an AB SCIEX QTRAP 5500 LC/MS/MS System (AB SCIEX Deutschland GmbH, Darmstadt, Germany) equipped with a Turbo V Source and an electrospray-ionization (ESI) probe. The system was controlled with the Analyst 1.5.1 software (AB SCIEX).
A total volume of 300 ml urine (or standard or blank) was mixed with 25 ml of internal standard solution of D16-BPA, 150 ml of ammoniumacetate buffer (1 M, pH 5.0) and 6 ml of b-glucuronidase/arylsulfatase Type HP-2 from Helix pomatia (Sigma-Aldrich Chemie GmbH, Steinheim, Germany). Hydrolyses were performed at 37 1C for 4 h. Then, 100 ml of the sample was loaded onto a LiChrospher RP8 ADS 25 mm column (25 Â 4 mm; Merck KGaA, Darmstadt, Germany) and transferred in backflush mode onto a reversed phase Waters Atlantis T3 analytical column (3.0 Â 150 mm; 3 mm; Waters GmbH, Eschborn, Germany). The gradient was composed of water (Merck, Lichrosolv) and acetonitrile (Merck, hypergrade). We monitored two precursor/product ion transitions (m/z) for BPA (227/133, 227/93) and D16-BPA (241/142). The limit of detection (LOD) was 0.05 mg/l (based on a signal-to-noise ratio of 3) and the limit of quantification (LOQ) was 0.1 mg/l (based on a signal-to-noise ratio of 9). With the on-line methodology we were able to keep the laboratory blank value of BPA (caused by contamination with omnipresent BPA) below the LOD of 0.05 mg/l. The relative SDs for native controls were at 6.5% (Q low ; 2.9 mg/l) and 3.4% (Q high ; 11.8 mg/l) for the within-series imprecision and at 5.6% (Q low ) and 3.4% (Q high ) for the day-to-day imprecision. The relative recovery from spiked (10 mg BPA/l) individual urine samples (creatinine content between 0.17 and 2.4 g/l) was at 96.8% (88.5--104%). To ensure data accuracy and precision we included internal quality control (QC) samples at two concentration levels, standards and reagent blanks in each batch of samples.
Determination of Unconjugated BPA in Urine
The concentration of unconjugated BPA was determined according to the methodology described above but without the hydrolyse step (no enzyme, no incubation). Calibration curves, QC samples (native urine spiked with unconjugated BPA to 10 mg/l) and reagent blanks were treated the same way. The methods characteristics were the same as with enzymatic deconjugation.
Determination of Total and Unconjugated BPA in Plasma
The methodological approach described above for urine samples can be applied for plasma samples with only minor modifications. 24, 25 To decrease the viscosity of the plasma samples, instead of 300 ml of urine (or standard, or blank) and 150 ml of ammoniumacetate buffer we used 150 ml plasma (or standard, or blank) and 300 ml of ammoniumacetate buffer. The LOD was 0.05 mg/l and the LOQ was 0.1 mg/l.
Daily Intake Calculations
Based on the urinary BPA levels (total BPA) we calculated the daily BPA intake (DI) separately for each subject applying the following equation:
where uc BPA(total) is the concentration of BPA (total BPA determined after enzymatic hydrolyses) in mg/l; and uv 24 h is the 24 h urine volume (in liters) for each individual. The urinary excretion fraction f ue describes the amount of BPA excreted via urine within 24 h after oral application relative to the incorporated dose. This conversion rate has been determined in human metabolism studies by administration of isotope-labeled BPA and is set to a value of 1, as these studies indicate that close to 100% of the oral BPA is excreted via urine within 24 h after exposure as a conjugate (glucuronide or sulfate) or to a much lesser extent as unconjugated BPA. 12, 14, 15, 18 The daily intake values were normalized to the individual body weight (bw) in kg.
RESULTS AND DISCUSSION
Pilot Study Unconjugated and total BPA in urine samples from the years 1988 and 2008. Table 2 lists the results of the pilot study on unconjugated and total urinary BPA concentrations in the archived urine samples from the years 1988 and 2008. In the 60 urine samples, 58 samples had total BPA concentrations above the LOQ of 0.1 mg/l (96.7%) with a median (maximum) of 1.32 (14.5) mg/l for 1988 and slightly lower values with a median (maximum) of 1.04 (8.54) mg/l for 2008. Only six samples had unconjugated BPA levels above the LOQ (0.1 mg/l), two from the year 1988 and 4 from the year 2008, at comparably low levels from 0.1 to 0.24 mg/l. The maximum value for total BPA (14.5 mg/l) and the maximum value for unconjugated BPA (0.24 mg/l) were measured in the same sample. In the six urine samples with values for both unconjugated and total BPA, unconjugated BPA levels constituted between 1.2% and 11.6% (mean: 4.6%) of the total BPA.
Our results are in agreement with findings from human metabolism studies that showed that BPA administered orally is quickly and almost completely biotransformed into the conjugated metabolites BPA-glucuronide and BPA-sulfate and rapidly excreted in urine. 12, 14, 18, 20 Our results are also in agreement with reports on the percentage of glucuronide and sulfate conjugates of BPA in 30 urine samples of a group of adult volunteers with no known occupational exposure collected between 2000 and 2004 in the Atlanta area. 15 In this study a share of B10% of unconjugated BPA in relation to total BPA was reported. Similar findings were reported by the same group for 41 premature infants. 26 Unconjugated BPA concentrations in these infants were also an order of magnitude lower than total BPA concentrations. BPA concentrations in these premature infants (undergoing intensive therapeutic medical interventions) were B10 times the concentrations in the general population. Of interest, the concentrations of unconjugated and conjugated species of BPA showed a linear relationship over the whole range of total BPA concentrations measured. In contrast, in a Korean general population study, the percentage of BPA excreted in its unconjugated form was B30%, and thus contradicts the previous findings. 27 Reasons for these differences can be manifold. Speculations range from ethnic-specific differences in metabolism to contamination issues. This issue can only be solved by metabolism studies performed with labeled BPA, thus excluding the risk of external contamination.
The main outcome of our pilot study is, therefore, that we have no indications (based on the share of unconjugated BPA in these samples) that either external BPA contamination or degradation of the BPA conjugates occurred during the sampling process, the storage or the handling of the urine samples of the ESB. We therefore regard both the unconjugated and the conjugated BPA, thus the total BPA in urine, as a valid biomarker of BPA exposure applicable for studying the BPA exposure in the urine samples of the ESB. The pilot study also illustrates that because of its low detection rate, unconjugated BPA is only a weak parameter to describe exposures of the general population to BPA, even if the LOQ of the analytical method was rather low (0.1 mg/l) and laboratory blank values were below this LOQ.
Main Study
Total BPA in 600 24 h urine samples from 1995 to 2009. Total BPA concentrations measured in the 600 24 h urine samples are presented in Table 3a (values in mg/l) and Table 3b (values in mg/g creatinine). We detected total BPA at concentrations ranging from 0.1 to 34.6 mg/l (0.2 to 42.6 mg/g creatinine) in 99.8% of the samples. Only one sample was below the limit of quantification of 0.1 mg/l. The geometric mean and 95th percentile concentrations were 1.55 mg/l (1.76 mg/g creatinine) and 7.37 mg/l (7.31 mg/g creatinine). The females had slightly lower total BPA concentrations than the males on a mg/l basis (geometric mean: Table 4 ). Despite possible local differences in usage patterns and exposure scenarios, and despite the ESB samples being 24 h urine compared with spot samples from the American continent, the exposure situation seems to be very uniform on both sides of the Atlantic, with geometric mean concentrations between 1.33 and 1.99 mg/l and 95th percentiles between 6.34 and 13.2 mg/l.
However, the focus of the ESB study was the investigation of temporal trends of BPA exposures over the last decades and a reliable estimation of the daily BPA intake based on 24 h urine samples. On first sight, the ESB data in mg/l suggest a temporal trend to lower BPA exposure levels from 1995 to 2009, with a small but steady decrease from geometric mean values of B2.0 to 1.3 mg/l. This trend, however, cannot be observed in the creatinine-corrected values (geometric mean values between 1.54 mg/g in 2005 and 1.98 mg/g in 1999). Indeed, by comparing the geometric mean values of BPA (in mg/l) with the geometric mean total urine volume of the 24 h urine samples (in ml), one can observe countervailing trends, with the decreasing BPA concentrations (in mg/l) being annulled by increasing total urine volumes of the 24 h urine samples (see Figure 1 ). An increase in 24 h urine volumes of the ESB is a phenomenon that is observed in all ESB 24 h urines and can be explained by various health campaigns (in Germany) to provide the body with sufficient water intake (of at least 2 liters per day).
Daily BPA intake in mg/kg b.w./day. The calculation of the daily BPA intake (in mg/kg b.w./day) in the ESB data set can reliably be performed based on the mg/l concentrations, the 24 h urine volume of each sample and the body weight of each individual. To take account of differently diluted urine samples (e.g., by creatinine correction) as needed for spot urine samples is not an issue in the daily intake calculation based on 24 h urine samples. Results for the daily BPA intake calculated from 596 samples of the ESB data set are presented in Table 5 . For four individuals the daily intake could not be calculated, because their body weights were missing in the data set. Samples below the LOQ (only one sample in the study population was below the LOQ of 0.1 mg/l) were set to half the LOQ. For all 596 subjects investigated we calculated a geometric mean intake of 0.039 mg BPA/kg b.w./day and a 95th percentile of 0.171 mg BPA/kg b.w./day. Maximum daily intakes were below 1 mg/kg b.w./day. The daily intakes did not differ between the male and female subsets of the study population (geometric mean: 0.039 vs 0.040 mg/kg b.w./day; 95th percentile: 0.165 vs 0.170 mg/kg b.w./day; see Table 5 ). Daily intake levels calculated from other human biomonitoring data are in the same range, as summarized in Vandenberg et al. 6 For the NHANES 2005--2006 data set of the 20--39-year-old subpopulation, geometric mean daily intakes were calculated to be 0.0385 mg/kg b.w./day, and the 95th percentile to be 0.220 mg/kg b.w./day, 8 again very similar to the daily intakes calculated for the ESB study group. Contrary to Lakind and Naiman, 8 we did not find significantly lower daily intakes for females compared with males. For the German Environmental Survey on Children 2003--2006 (GerES IV) with children aged 3--14 years, the geometric mean daily intake (0.06 mg/kg b.w./day) and the 95th percentile (0.37 mg/kg b.w./day) were higher than for the German students of our study. 3 Also, the maximum daily intake calculated in these children was considerably higher (7 vs 0.95 mg/kg b.w./day). In general, current data from human biomonitoring studies suggest that children might have significantly higher daily BPA intakes than adults, 3, 8 a finding that has been reported before for other nonpersistent environmental (mainly food-borne) contaminants like phthalates. 7,28--30 In investigating the daily BPA intake over the course of the years from 1995 to 2009, the geometric mean daily intake fluctuated only within small margins between 0.035 and 0.044 mg/kg b.w./ day (see Figure 2) . Arithmetic mean and 95th percentile intake values seemed to be declining gradually from 1995 to 2001/2003. This decline, however, did not continue from 2003 on and seemed to be reversed to some extent from 2003 on. The highest daily intake was actually measured in a sample from 2008 (0.95 mg BPA/ kg b.w./day). For the study group investigated here, 20--29-yearold German students from the German university city Muenster, we can therefore conclude that exposure to BPA has been rather constant over the past 15 years with regard to both the mean values and the upper percentiles. We could not observe a trend to decreasing daily intakes, as we previously have observed for some phthalates due to regulatory measures (ban of certain phthalates) or voluntary substitutions by the industry. 21, 31 It remains to be seen whether similar developments, like the ban of BPA in certain products (since 2010/2011 in Europe) or the special marketing of BPA-free products, find their reflection in the samples of the ESB that are collected on an ongoing basis.
Daily BPA intake compared with environmental health benchmarks. The daily BPA intake calculated for the ESB study group (95th percentile: 0.17 mg/kg b.w./day; maximum: 0.95 mg/kg b.w./day) is considerably below the RfD of the US EPA and the TDI of the European Food Safety Authority (EFSA) of 50 mg/kg b.w./day (refs 32--34) . However, it has to be pointed out that the ESB covers by definition only a small subset of the German population (students, 20--29 years old). Daily intake calculations from human biomonitoring data for children, for example, from NHANES or GerES IV suggest that children might be exposed to considerably higher BPA levels than adults, 3, 8 and bottle-fed babies might be additionally exposed to BPA via contaminated baby formulas or BPA from polycarbonate bottles. 6, 35 Apart from establishing reliable exposure estimates based on human biomonitoring data, controversial discussions are led in recent years about the reliability of the current TDI resp. RfD to protect from the effects observed at ''low dose'' exposures in animal experiments and human epidemiological studies. 19, 36, 37 Although (total) BPA in urine is generally regarded as the ideal biomarker to reliably and integrally measure the quantity of all external exposures to BPA (and deriving the daily intake), circulating unconjugated BPA in blood (or serum) is of special interest for toxicological and mechanistic evaluations, because only unconjugated BPA is regarded as hormonally active. 18, 36, 38, 39 Total and unconjugated BPA in ESB plasma samples. A total of 60 plasma samples have been selected based on the results of the total BPA levels in urine to reflect the whole bandwidth of exposure. Because of this selection process, these plasma samples cannot be regarded to be representative for the whole ESB study group, although they covered all years between 1995 and 2009 and were equally distributed between males and females. Out of the 60 plasma samples, only 7 samples had total BPA levels above the LOQ of the analytical method of 0.1 mg/l. For total BPA the 95th percentile was 0.16 mg/l and the maximum concentration measured was 0.40 mg/l. In these few samples the predominant share (90--100%) of total BPA was present as unconjugated BPA. The total BPA levels that we measured in the ESB plasma samples are considerably lower than total or unconjugated BPA levels measured in most other studies, as summarized in, for example, Vandenberg et al. 6 or Bloom et al. 40 We can only speculate on methodological differences in terms of detection technique (selectivity), LOQ (sensitivity) and within laboratory as well as preanalytical blank issues causing such different results. We also regard our results critical in terms of the ratio of unconjugated to conjugated BPA. In accordance to the highly reliable metabolism studies from Volkel et al., 14 Sieli et al. 38 and Taylor et al. 39 (all of these studies have been performed with isotope-labeled BPA), we would expect unconjugated BPA to be present in considerably lower concentrations than conjugated BPA. These findings have recently been confirmed in a clinical exposure study investigating the internal exposure of adult humans to BPA and the relationship between the serum and urinary pharmacokinetics of BPA after ingestion of specified, BPA-enriched meals. 41 This clinical study was performed under a strict regime and protocol to control for preanalytical and analytical BPA contamination. All the above studies are in agreement that o5% of the total BPA in blood should be present as unconjugated BPA. Either a degradation of the conjugated to the unconjugated BPA in the stored ESB plasma samples or a trace-level contamination during the preanalytical phase (e.g., sample collection) might have led to the disparities in the unconjugated to conjugated BPA ratios. Also, based on these studies, their BPA doses and the BPA concentrations (unconjugated and conjugated) that they found in blood after the doses, we would not expect to find unconjugated BPA at concentration levels above the LOQ of 0.1 mg/l even at the highest calculated daily BPA intake for the ESB study group of 1 mg/kg. However, at a dose of 1 mg/kg, total BPA concentrations in plasma of 0.5 mg/l might be reached, which would be in accordance with a total BPA concentration of 0.40 mg/l that we found as a maximum value. Therefore, assuming the worst case scenario that the conjugated BPA degraded to unconjugated BPA and the total BPA we measured therefore still represents the body burden to BPA we compared the total serum BPA concentrations with the total urinary BPA concentrations. As can be seen in Figure 3 , there is no significant association between urine and plasma BPA concentrations. However, as shown both in the above metabolism studies and the clinical exposure study, 41 urinary peak BPA concentrations are lagging behind the plasma peak concentrations by B1 h and the elimination half-lives of BPA are very short. We therefore cannot expect the BPA determined in the 24 h urine samples to correlate with the BPA determined in the spot blood/plasma samples donated after the collection time of the 24 h urine samples. On an individual basis, because of the known BPA elimination kinetics, neither spot urine nor spot blood samples can be regarded as reliable indicators of BPA exposure within the last 24 h. It can also be seen that the (total) BPA concentrations in plasma are generally lower by approximately two orders of magnitude compared with the (total) BPA concentrations in urine, with most of the BPA plasma levels below the limit of quantification, thus further questioning the applicability of blood/plasma BPA in its conjugated form and even more in its unconjugated form as a reliable and meaningful indicator of BPA exposure in population-based studies.
CONCLUSION
Currently, we can only interpret the above results and findings as follows: taking into account the tremendous problems that have to be overcome in the analyses of BPA in blood/serum (contamination, low limit of quantification) and the possible pitfalls during sample collection and storage (contamination), we see BPA in blood/serum only applicable as an internal measure of BPA exposure in controlled metabolism/kinetic studies performed with labeled BPA or in clinical studies with strictest contamination control. 41 Up to now, BPA in urine (determined as total BPA, but with checking the ratio of unconjugated to conjugated BPA) has to be regarded as the only sufficiently reliable biomarker of exposure in population-based studies. A strict contamination control with regard to omnipresent BPA is of vital importance in both human biomonitoring and toxicological studies.
We have thoroughly checked the integrity of the urine samples stored by the ESB with regard to possible external BPA contamination and with regard to a possible degradation of the conjugated BPA species to unconjugated BPA. We are highly confident that the ESB urine from 1995 to 2009 can be used to reliably measure and evaluate the internal exposure to BPA and that the 24 h urine samples can also be used to reliably extrapolate to the extent of external exposure to BPA, expressed as the daily BPA intake in mg/kg b.w./day. For the ESB study group we can conclude that the daily BPA intake has been very constant over the past 15 years investigated. The geometric mean daily BPA intake of 0.17 mg/kg b.w./day and the maximum daily intake of 0.95 mg/kg b.w./day are sufficiently below the current TDI of 50 mg/kg b.w./day. Whether this TDI is low enough to also protect from possible low-dose effects of BPA remains to be resolved in the scientific debate in the years to come. 
